氯吡林柠檬酸 | 148-64-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 氯吡林柠檬酸
• 英文名称: Chlorothen citrate
• 英文别名: N'-[(5-chlorothiophen-2-yl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine;2-hydroxypropane-1,2,3-tricarboxylic acid
• CAS: 148-64-1
• 化学式: C20H26ClN3O7S
• 分子量: 488.0
• InChiKey: LLQVTRFPENCFFC-UHFFFAOYSA-N

物化性质

• 熔点：
  112-116°

计算性质

• 辛醇/水分配系数(LogP)：
  2.12
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  180
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• An otorhinological drug delivery device
  申请人：Schering Oy

  公开号：EP1438942A1

  公开（公告）日：2004-07-21

  The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof.

  本发明涉及一种包含至少一种药用活性剂的耳鼻喉给药装置。根据本发明，该装置包括一个包含所述至少一种药物活性剂的芯体，其中所述芯体由弹性体组合物制成，该弹性体组合物选自聚（二甲基硅氧烷）、硅氧烷基弹性体（包含连接到硅氧烷单元S原子上的3,3,3-三氟丙基）、硅氧烷基弹性体（包含聚（环氧烷）基团）及其混合物组成的组。
• Alternating sympathomimetic therapy for the treatment of respiratory ailments
  申请人：Sovereign Pharmaceuticals, LLC

  公开号：US10098856B2

  公开（公告）日：2018-10-16

  A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof.

  一种用于缓解呼吸系统疾病的组合剂量单位和一种使用这种组合剂量单位的缓解呼吸系统疾病的方法。这些剂量单位包括一个或多个由伪麻黄碱和/或其药学上可接受的盐组成的第一剂量单位和一个或多个由苯肾上腺素和/或其药学上可接受的盐组成的第二剂量单位。
• Unit dose of material in system and method
  申请人：Lovercheck R. Dale

  公开号：US20050202085A1

  公开（公告）日：2005-09-15

  The invention provides a unit dose of an orally consumable material, having a predetermined pharmaceutically effective amount of at least one nonprescription discomfort reliever and a predetermined nutritionally effective amount of at least one nutritional supplement. Each unit dose may be in a container having indications of the amount discomfort reliever and the amount of nutritional supplement in each unit dose. Instructions are provided for consuming the material for discomfort relief and supplementing nutrition. Consumption of the unit dose simultaneously relieves discomfort and supplements nutrition.

  本发明提供了一种单位剂量的口服材料，其中含有预定药效量的至少一种非处方药不适缓解剂和预定营养有效量的至少一种营养补充剂。每个单位剂量可装在一个容器中，容器上标明每个单位剂量中的不适缓解剂用量和营养补充剂用量。提供了食用该材料以缓解不适和补充营养的说明。服用单位剂量可同时缓解不适和补充营养。
• Phenylepherine containing dosage form
  申请人：Srinivasan Viswanathan

  公开号：US20060057205A1

  公开（公告）日：2006-03-16

  A pharmaceutical dosage form which comprises phenylepherine or a pharmaceutically acceptable salt thereof and a second drug. The dosage form provides a plasma concentration within the therapeutic range of the second drug over a period which is coextensive with at least about 70% of the period over which the dosage form provides a plasma concentration within the therapeutic range of phenylepherine. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

  一种药物剂型，由苯乙哌啶或其药学上可接受的盐和第二种药物组成。该剂型在第二种药物的治疗范围内提供血浆浓度的时间段，至少与该剂型在苯酪氨酸的治疗范围内提供血浆浓度的时间段的约 70% 相一致。本摘要既不打算对本说明书中公开的发明进行定义，也不打算以任何方式限制本发明的范围。
• Otorhinological delivery device
  申请人：Haapakumpu Timo

  公开号：US20060067982A1

  公开（公告）日：2006-03-30

  The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Siatoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof, and a membrane encasing said core, said membrane being made of a same or a different elastomer composition than said core, said elastomer composition being selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Siatoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof. The invention is characterized in that the pharmaceutically active agent is selected from the group comprising anti-allergic agents, anti-inflammatory agents, anti-fungicides, glucocorticoids and mixtures thereof.

  本发明涉及一种包含至少一种药用活性剂的耳鼻喉给药装置。根据本发明，该装置包括一个包含所述至少一种药物活性剂的核心，其中所述核心由弹性体组合物制成，该组合物选自聚（二甲基硅氧烷）、硅氧烷基弹性体（包含连接到硅氧烷单元硅原子上的 3,3,3-三氟丙基）、硅氧烷基弹性体（包含聚（环氧亚烷基）基团）及其混合物组成的组、以及包覆所述芯材的膜，所述膜由与所述芯材相同或不同的弹性体组合物制成，所述弹性体组合物选自聚二甲基硅氧烷、硅氧烷单元硅原子上附有 3,3,3-三氟丙基的硅氧烷基弹性体、聚环氧烷基硅氧烷基弹性体及其混合物组成的组。本发明的特征在于，药物活性剂选自抗过敏剂、抗炎剂、抗真菌剂、糖皮质激素及其混合物。